PI3K and mTOR inhibitors - a new generation of targeted anticancer agents

被引：99
|
作者：
Brachmann, Saskia [1 ]
Fritsch, Christine [1 ]
Maira, Saveur-Michel [1 ]
Garcia-Echeverria, Carlos [1 ]
机构：
[1] Novartis Inst Biomed Res, Basel, Switzerland
来源：
CURRENT OPINION IN CELL BIOLOGY | 2009年 / 21卷 / 02期
关键词：
PHOSPHATIDYLINOSITOL 3-KINASE/MAMMALIAN TARGET; RAPAMYCIN INHIBITOR; DRUG DISCOVERY; PATHWAY; KINASE; CANCER; ACTIVATION; NVP-BEZ235; ANTITUMOR; GROWTH;
D O I：
10.1016/j.ceb.2008.12.011
中图分类号：
Q2 [细胞生物学];
学科分类号：
071009 ; 090102 ;
摘要：
Epidemiological and experimental studies support an important role of the phosphoinosite 3-kinase (PI3K)/mammalian target of rapamycin (mTOR) pathway in the biology of human cancers. Over the past few years a number of components of this signaling cascade have been the subject of intense drug discovery activities. This article summarizes progress made in the identification of kinase inhibitors of PI3K and mTOR, with an emphasis placed on drugs currently undergoing clinical trials. Potential combination strategies, safety concerns, and resistance mechanisms for this new generation of anticancer agents are also discussed.
引用
收藏
页码：194 / 198
页数：5
相关论文
共 50 条
  • [1] Recent advances in PI3K/PKB/mTOR inhibitors as new anticancer agents
    Occhiuzzi, Maria Antonietta
    Lico, Gernando
    Ioele, Giuseppina
    De Luca, Michele
    Garofalo, Antonio
    Grande, Fedora
    [J]. EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, 2023, 246
  • [2] QSAR modeling and structure based virtual screening of new PI3K/mTOR inhibitors as potential anticancer agents
    Oluic, Jelena
    Nikolic, Katarina
    Vucicevic, Jelica
    Gagic, Zarko
    Filipic, Slavica
    Agbaba, Danica
    [J]. PROCEEDINGS OF THE INTERNATIONAL CONFERENCE ON MEDICAL AND BIOLOGICAL ENGINEERING 2017 (CMBEBIH 2017), 2017, 62 : 379 - 383
  • [3] Activation of PI3K/Akt/mTOR Pathway and Dual Inhibitors of PI3K and mTOR in Endometrial Cancer
    Chen, Jiezhong
    Zhao, Kong-Nan
    Li, Rui
    Shao, Renfu
    Chen, Chen
    [J]. CURRENT MEDICINAL CHEMISTRY, 2014, 21 (26) : 3070 - 3080
  • [4] PI3K Inhibitors and Their Role as Novel Agents for Targeted Therapy in Lymphoma
    Vladimir Sapon-Cousineau
    Sasha Sapon-Cousineau
    Sarit Assouline
    [J]. Current Treatment Options in Oncology, 2020, 21
  • [5] PI3K Inhibitors and Their Role as Novel Agents for Targeted Therapy in Lymphoma
    Sapon-Cousineau, Vladimir
    Sapon-Cousineau, Sasha
    Assouline, Sarit
    [J]. CURRENT TREATMENT OPTIONS IN ONCOLOGY, 2020, 21 (06)
  • [6] THE ROLE OF CDK AND PI3K/MTOR INHIBITORS
    Andre, Fabrice
    [J]. BREAST, 2015, 24 : S25 - S25
  • [7] Protein and lipid kinase inhibitors as targeted anticancer agents of the Ras/Raf/MEK and PI3K/PKB pathways
    Garcia-Echeverria, Carlos
    [J]. PURINERGIC SIGNALLING, 2009, 5 (01) : 117 - 125
  • [8] Protein and lipid kinase inhibitors as targeted anticancer agents of the Ras/Raf/MEK and PI3K/PKB pathways
    Carlos García-Echeverría
    [J]. Purinergic Signalling, 2009, 5 : 117 - 125
  • [9] Predictive and pharmacodynamic (PD) markers of PI3K pathway inhibitors: focus on PI3K, AKT and mTOR inhibitors
    Tabernero, J.
    [J]. EUROPEAN JOURNAL OF CANCER, 2011, 47 : S6 - S6
  • [10] Combinations of PI3K inhibitors with targeted oncology agents in multicellular spheroid models
    Dexheimer, Thomas S.
    Silvers, Thomas
    Coussens, Nathan P.
    Said, Rabih
    Teicher, Beverly A.
    Doroshow, James H.
    [J]. MOLECULAR CANCER THERAPEUTICS, 2023, 22 (12)
12345